Enliven Therapeutics, Inc. logo ELVN - Enliven Therapeutics, Inc.

NEXT EARNINGS: Mar 12, 2026 (in 15 days) EPS Est: $-0.42 | Rev Est: $8330
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 5
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $43.33 DETAILS
HIGH: $52.00
LOW: $39.00
MEDIAN: $39.00
CONSENSUS: $43.33
UPSIDE: 53.00%
Market Cap: 1.68B
Volume: 775,280
Avg Volume: 1,019,542
52 Week Range: 13.3-30.22
Sector: Healthcare
Industry: Biotechnology
Beta: 1.14
Last Dividend: $N/A
Exchange: NASDAQ
Country: US
Employees: 62
IPO Date: 2020-03-12
EPS (TTM): -1.89
P/E Ratio: -11.90
Revenue (TTM): N/A
Total Assets: 325.76M
Total Debt: N/A
Cash & Equiv: 124.12M
Rev Growth (5Y): N/A
EPS Growth (5Y): N/A
FCF Growth (5Y): N/A
ROCE: -33.7%
Debt/Equity: N/A

Earnings History

Date EPS Actual EPS Est EPS Surprise Rev Actual Rev Est Rev Surprise
2025-11-12 $-0.32 $-0.43 +25.6% $8330
2025-08-13 $-0.49 $-0.53 +7.5%
2025-05-14 $-0.57 $-0.51 -11.8%
2025-03-13 $-0.46 $-0.53 +13.2%
2024-11-13 $-0.48 $-0.52 +7.7%
2024-08-13 $-0.41 $-0.58 +29.3%
2024-05-14 $-0.54 $-0.58 +6.9%
2024-03-14 $-0.47 $-0.56 +16.1% $440000

Track Record

Statements >
Metric 2024 2023 2022 2021 2020 2019 2018 2017
Revenue 0 0 0 0 0 0 0 0
Net Income (89.02M) (71.58M) (37.66M) (24.74M) (18.97M) (23.46M) (11.34M) 0
EPS -1.89 -2.01 -6.03 -3.17 -4.31 -5.43 -2.62 0.00
Total Assets 325.76M 271.87M 83.30M 113.33M 90.84M 33.30M 7.71M 10.22M
Total Debt 0 335,000 323,000 159,000 0 0 0 660,000
Cash & Equivalents 124.12M 100.14M 75.54M 110.02M 47.70M 4.94M 7.38M 9.67M
Operating Cash Flow (73.19M) (61.27M) (32.08M) (19.13M) (8.53M) (21.88M) (8.78M) (8.79M)
Free Cash Flow (73.24M) (61.42M) (32.69M) (19.32M) (8.99M) (22.02M) (8.78M) (8.79M)
FCF per Share -1.56 -1.73 -5.23 -2.47 -2.05 -5.10 -2.03 -2.03
Book Value 309.85M 245.91M (76.83M) 106.86M 84.44M (48.85M) (26.32M) (15.53M)
Cash & ST Investments 313.44M 253.15M 75.54M 110.02M 88.22M 28.91M 7.38M 9.67M
ROC Equity -0.29 -0.29 N/A -0.23 -0.22 N/A N/A N/A